Reboxetine-Mesilate shortage status
1 active shortage notice across 1 country.
Last updated 2 Aug 2026 · sourced from official medicines regulators
- Generic name (INN)
- Reboxetine-Mesilate
- Brand names
- EDRONAX reboxetine
- Class
- Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
Where Reboxetine-Mesilate is in shortage
Why Reboxetine-Mesilate is in shortage
- product discontinuation — e.g. “Product discontinued / no longer available on the Australian market.” (Australia)
Recent shortage history
- Australia: resolved 29 Apr 2026 (began 29 Apr 2026)
- Australia: resolved 12 Feb 2026 (began 12 Feb 2026)
Frequently asked questions
Is Reboxetine-Mesilate currently in shortage?
Yes. As of the latest regulator updates, Reboxetine-Mesilate has 1 active shortage notice across 1 country (Australia). Status is refreshed daily from official regulatory sources.
Why is Reboxetine-Mesilate in shortage?
Regulators attribute the current Reboxetine-Mesilate shortages to product discontinuation. The exact cause varies by country and product — each notice on this page links to the official source.
Where does this Reboxetine-Mesilate shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Get alerted when Reboxetine-Mesilate status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.